Back to search results

WISDOM Study: Continuous Renal Replacement Therapy for Acute Kidney Injury

This study, called WISDOM, is looking at how different doses of Continuous Renal Replacement Therapy (CRRT) affect critically ill patients with acute kidney injury (AKI). CRRT is a type of continuous dialysis used in the intensive care unit (ICU) for patients with kidney failure. Researchers want to see if a lower dose of CRRT works just as well as the standard dose, and if it might even shorten the time patients need CRRT or help their kidneys recover better. About 100 people aged 18 or older who weigh at least 55 kg and are starting or have recently started CRRT for AKI can join. The main goal is to compare the delivered CRRT dose-intensity over about one month.

Study design
This is an interventional study planning to enroll 100 participants. It compares two different dose-intensities of Continuous Renal Replacement Therapy (CRRT).
What's involved
You would need to be 18 years or older, weigh at least 55 kg, and be starting or have recently started CRRT for AKI. You should also be expected to survive and receive CRRT for at least 48 hours.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, CRRT dose-intensity, will be measured through study completion, an average of 1 month.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06446739

LoW Dose-Intensity vs. Standard Dose-Intensity COntinuous Renal ReplaceMent Therapy in Critically Ill Patients (WISDOM)

Recruiting
NAAges 18+InterventionalTreatment
University of Alberta
~100 participants
Updated 2026-07-09 on ClinicalTrials.gov
What's tested:Continuous Renal Replacement Therapy (CRRT)

At a glance

Recruiting sites
10 of 10 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Difference in delivered CRRT dose-intensity
Measured over Through study completion, an average of 1 month.

Conditions

Acute Kidney Injury
Dialysis; Complications

Explore related trials

Acute Renal Failure

Where it's being run

10 sites across 5 states
Alberta4
Ontario3
Minnesota1
Saskatchewan1
United Kingdom1

Study leadership

  • Sean M Bagshaw, MD · PRINCIPAL_INVESTIGATOR · University of Alberta
  • Ron Wald · PRINCIPAL_INVESTIGATOR · St. Michael's Hospital (Unity Health)

Who to contact

Sean M Bagshaw, MD
[email protected]
780-248-1256
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

age ≥ 18 years
weight ≥ 55 kg
plan to initiate CRRT or within 24 hours of having started CRRT for AKI
expected to survive and receive CRRT for a duration of ≥ 48 hours
able to provide informed consent or have an authorized representative provide consent after being informed on the details and risks of the trial unless a deferred consent process is approved by local Research Ethics Board (REB).

Exclusion

indication for sustained higher dose-intensity CRRT as designated by the attending clinicians
end-stage kidney disease receiving maintenance dialysis
receipt of any RRT for AKI during the current hospitalization
inability to comply with the requirements of the study protocol.

What this trial measures

  • Difference in delivered CRRT dose-intensityThrough study completion, an average of 1 month.

    This pilot trial will target detection of a minimum difference of 10 mL/kg/hr in delivered dose-intensity.